.Pharmacolibrary.Drugs.ATC.A.A02BD17

Information

Vonoprazan and amoxicillin is a combination therapy used mainly for the eradication of Helicobacter pylori infection. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits gastric acid secretion, while amoxicillin is a broad-spectrum beta-lactam antibiotic. This combination is clinically approved and used, particularly in Asia, for H. pylori eradication regimens as an alternative to traditional proton pump inhibitor-based therapies.

Pharmacokinetics

Pharmacokinetic parameters are estimated based on monotherapy data for vonoprazan and amoxicillin in healthy adult subjects, due to lack of published combined PK model data for fixed-dose or co-administered combination.

References

1. Echizen, H (2016). The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical pharmacokinetics 55(4) 409–418. DOI:10.1007/s40262-015-0326-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26369775

Revisions

• 06/2025 initial generated model